NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. reminds Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) investors that it is investigating potential claims on their behalf concerning whether the company’s officers and board of directors violated the federal securities laws.
On November 6, 2015, Dr. Reddy’s disclosed that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India. Dr. Reddy’s said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the problems. The manufacturing plants account for more than 10% of Dr. Reddy’s sales.
Following this news, shares of Dr. Reddy’s fell $11.75 per share, or over 18%, to close at $53.50 per share on November 6, 2015.
If you purchased Dr. Reddy’s securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.